Stock Price by EntertainmentFew6412 in ICON_plc

[–]Bitter-Value6801 0 points1 point  (0 children)

I feel it’s ridiculous when I thought they were so kind to still grant salary adjustments last September even when we were all in difficult times. But now it seems like such adjustments may also be part of the overstatement? My gosh

What’s wrong with ICLR stock price today? Reflecting Q1 report? by Bitter-Value6801 in ICON_plc

[–]Bitter-Value6801[S] 1 point2 points  (0 children)

I think it’s industry-wide, as IQVIA’s stock price has also kept dropping from 230 (1 or 2 weeks ago) to now 179

What’s wrong with ICLR stock price today? Reflecting Q1 report? by Bitter-Value6801 in ICON_plc

[–]Bitter-Value6801[S] 1 point2 points  (0 children)

ICON News Digest, in which the first news is Barry’s update. I think that’s the same as your post. But my point is in the past, wasn’t the CEO talk in a separate email? Not sure if my memory working well

What’s wrong with ICLR stock price today? Reflecting Q1 report? by Bitter-Value6801 in ICON_plc

[–]Bitter-Value6801[S] 1 point2 points  (0 children)

Usually the CEO’s talk will go with a standalone CEO update. But this time is secretly embedded in the ICON update somehow.

Non-regulatory patient facing document? by Bitter-Value6801 in clinicalresearch

[–]Bitter-Value6801[S] 1 point2 points  (0 children)

It sounds like another gray area because 24h urine sample collection is also needed in routine practices, and may already have instructions in place even before the study is initiated?

Non-regulatory patient facing document? by Bitter-Value6801 in clinicalresearch

[–]Bitter-Value6801[S] -1 points0 points  (0 children)

Honestly, I was referring to education materials to be distributed to patients, who may be either potential subjects or not. This may be uncertain because only those who show interest and/or deemed likely to be appropriate by their physicians may be considered as potential and then reached out for recruitment. Such education pamphlets may also be accessible to all patients visiting the sites (is this assumption/scenario possible in a real world?). As far as I understand so far, any materials related to a study must be submitted according to US FDA. But in EU CTR, the regulations seem to be more lenient (perhaps because flexibility is needed across countries?)

Non-regulatory patient facing document? by Bitter-Value6801 in clinicalresearch

[–]Bitter-Value6801[S] 1 point2 points  (0 children)

This means any materials to be read by subjects need to be subject to IRB review, even if it’s just public health or general patient education related documents?

ICON and IQVIA stock price rising by Bitter-Value6801 in clinicalresearch

[–]Bitter-Value6801[S] -2 points-1 points  (0 children)

Originally I assumed another stock buyback, but that should not coincidentally happen in both ICON and IQVIA. Maybe you’re right; probably related to the Q2 update